GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (LTS:0SAN) » Definitions » PS Ratio

Sandoz Group AG (LTS:0SAN) PS Ratio : 1.81 (As of Dec. 14, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Sandoz Group AG's share price is CHF37.23826. Sandoz Group AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was CHF20.62. Hence, Sandoz Group AG's PS Ratio for today is 1.81.

The historical rank and industry rank for Sandoz Group AG's PS Ratio or its related term are showing as below:

LTS:0SAN' s PS Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 2.02
Current: 1.84

During the past 2 years, Sandoz Group AG's highest PS Ratio was 2.02. The lowest was 0.00. And the median was 0.00.

LTS:0SAN's PS Ratio is ranked better than
57.6% of 974 companies
in the Drug Manufacturers industry
Industry Median: 2.38 vs LTS:0SAN: 1.84

Sandoz Group AG's Revenue per Sharefor the six months ended in Jun. 2024 was CHF10.47. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was CHF20.62.

During the past 12 months, the average Revenue per Share Growth Rate of Sandoz Group AG was 100.30% per year.

Back to Basics: PS Ratio


Sandoz Group AG PS Ratio Historical Data

The historical data trend for Sandoz Group AG's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG PS Ratio Chart

Sandoz Group AG Annual Data
Trend Dec22 Dec23
PS Ratio
- 1.35

Sandoz Group AG Semi-Annual Data
Dec22 Jun23 Dec23 Jun24
PS Ratio - - - -

Competitive Comparison of Sandoz Group AG's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sandoz Group AG's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's PS Ratio distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's PS Ratio falls into.



Sandoz Group AG PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Sandoz Group AG's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=37.23826/20.624
=1.81

Sandoz Group AG's Share Price of today is CHF37.23826.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sandoz Group AG's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was CHF20.62.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Sandoz Group AG  (LTS:0SAN) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Sandoz Group AG PS Ratio Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sandoz Group AG Business Description

Address
Forum 1, Novartis Campus, Basel, CHE, CH-4056
Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as the first US biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in its pipeline.

Sandoz Group AG Headlines

No Headlines